Professor Andreas Hougaard Laustsen-Kiel (1987) heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine at the Technical University of Denmark and is specialized in antibody technologies.
He is also the CTO of Bactolife ApS, responsible for nanobody technology and discovery in this company.
Andreas is a Fellow of the Danish Academy of Technical Sciences, the Young Academy of Denmark, and the Young Academy of Europe.
He holds a PhD from the University of Copenhagen and an M.Sc.Eng. from DTU.
Andreas is a co-founder of Biosyntia, VenomAb, Antag Therapeutics, Chromologics, VenomAid Diagnostics, and Bactolife and is recognized as Denmark’s Coolest Engineer (Engineer The Future), was listed on Forbes 30 under 30 in 2017, and was a Top 35 Innovator under 35 by MIT Technology Review 2017.
Combined, Andreas has been (co-)responsible for securing USD 85+ million for his research and ventures, and has published 60+ peer reviewed articles.